MassMutual Private Wealth & Trust FSB Purchases 1,384 Shares of Thermo Fisher Scientific Inc. $TMO

MassMutual Private Wealth & Trust FSB raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.7% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 53,144 shares of the medical research company’s stock after buying an additional 1,384 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in Thermo Fisher Scientific were worth $21,548,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Chemistry Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 42.0% in the 2nd quarter. Chemistry Wealth Management LLC now owns 1,453 shares of the medical research company’s stock valued at $589,000 after purchasing an additional 430 shares in the last quarter. Atwood & Palmer Inc. boosted its stake in shares of Thermo Fisher Scientific by 0.5% in the 2nd quarter. Atwood & Palmer Inc. now owns 54,062 shares of the medical research company’s stock valued at $21,920,000 after purchasing an additional 274 shares in the last quarter. Granite Bay Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 33.1% in the 2nd quarter. Granite Bay Wealth Management LLC now owns 13,667 shares of the medical research company’s stock valued at $5,541,000 after purchasing an additional 3,395 shares in the last quarter. RMR Wealth Builders boosted its stake in shares of Thermo Fisher Scientific by 24.6% in the 2nd quarter. RMR Wealth Builders now owns 3,574 shares of the medical research company’s stock valued at $1,449,000 after purchasing an additional 705 shares in the last quarter. Finally, NBC Securities Inc. boosted its stake in shares of Thermo Fisher Scientific by 9.4% in the 2nd quarter. NBC Securities Inc. now owns 2,741 shares of the medical research company’s stock valued at $1,111,000 after purchasing an additional 235 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on TMO. William Blair assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an “outperform” rating on the stock. Barclays upgraded shares of Thermo Fisher Scientific from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $490.00 to $550.00 in a research report on Thursday, September 11th. Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research report on Thursday, July 24th. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Finally, HSBC reiterated a “hold” rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $592.24.

Thermo Fisher Scientific Stock Performance

TMO opened at $474.73 on Tuesday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company’s fifty day moving average price is $467.98 and its two-hundred day moving average price is $450.20. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $623.77. The company has a market cap of $179.26 billion, a price-to-earnings ratio of 27.46, a PEG ratio of 2.56 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the prior year, the business posted $5.37 EPS. The business’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Insider Activity at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.